is semaglutide compound being discontinued Compounded GLP-1 - & Tirzepatide Demand Rising for 'Bootlegged' Weight-Loss

Maintaining stable weight is essential for preserving results

Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Your lab results show unexpected changes (liver or kidney markers): Significant shifts in liver enzymes, kidney markers, or other lab values should be reviewed with your provider

Appetite suppression is an intended pharmacological effect rather than an adverse event, but some patients experience it as more pronounced than anticipated

KK: Writing review & editing, Writing original draft, Resources